Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

RAPT Therapeutics (RAPT)

RAPT Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RAPT
DateTimeSourceHeadlineSymbolCompany
23/05/202423:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
23/05/202423:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
23/05/202423:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
23/05/202423:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
23/05/202421:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
09/05/202413:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
09/05/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
09/05/202413:00GlobeNewswire Inc.RAPT Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
09/04/202417:00GlobeNewswire Inc.RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202421:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202413:08Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RAPTRAPT Therapeutics Inc
07/03/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202413:00GlobeNewswire Inc.RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
05/03/202421:30GlobeNewswire Inc.RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
22/02/202422:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
20/02/202421:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
20/02/202412:30GlobeNewswire Inc.RAPT Therapeutics Announces Clinical Hold on Studies Evaluating ZelnecirnonNASDAQ:RAPTRAPT Therapeutics Inc
14/02/202413:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
13/02/202413:00GlobeNewswire Inc.RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical OperationsNASDAQ:RAPTRAPT Therapeutics Inc
31/01/202413:00GlobeNewswire Inc.RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
02/01/202413:00GlobeNewswire Inc.RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
27/11/202313:00GlobeNewswire Inc.RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyNASDAQ:RAPTRAPT Therapeutics Inc
13/11/202313:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
13/11/202313:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
13/11/202313:00GlobeNewswire Inc.RAPT Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
03/11/202316:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
03/11/202316:00GlobeNewswire Inc.RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLCNASDAQ:RAPTRAPT Therapeutics Inc
01/11/202320:05GlobeNewswire Inc.RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in NovemberNASDAQ:RAPTRAPT Therapeutics Inc
23/10/202321:40Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RAPTRAPT Therapeutics Inc
18/10/202314:00GlobeNewswire Inc.RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RAPT